|
1
|
Hsieh JJ, Purdue MP, Signoretti S, Swanton
C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal
cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lebacle C, Pooli A, Bessede T, Irani J,
Pantuck AJ and Drakaki A: Epidemiology, biology and treatment of
sarcomatoid RCC: Current state of the art. World J Urol.
37:115–123. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Posadas EM and Figlin RA: Systemic therapy
in renal cell carcinoma: Advancing paradigms. Oncology (Williston
Park). 26:290–301. 2012.PubMed/NCBI
|
|
6
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gregory RI and Shiekhattar R: MicroRNA
biogenesis and cancer. Cancer Res. 65:3509–3512. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liang H, Ge F, Xu Y, Xiao J, Zhou Z, Liu R
and Chen C: miR-153 inhibits the migration and the tube formation
of endothelial cells by blocking the paracrine of angiopoietin 1 in
breast cancer cells. Angiogenesis. 21:849–860. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vosgha H, Ariana A, Smith RA and Lam AK:
miR-205 targets angiogenesis and EMT concurrently in anaplastic
thyroid carcinoma. Endocr Relat Cancer. 25:323–337. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kinoshita T, Hanazawa T, Nohata N, Kikkawa
N, Enokida H, Yoshino H, Yamasaki T, Hidaka H, Nakagawa M, Okamoto
Y and Seki N: Tumor suppressive microRNA-218 inhibits cancer cell
migration and invasion through targeting laminin-332 in head and
neck squamous cell carcinoma. Oncotarget. 3:1386–1400. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Uesugi A, Kozaki K, Tsuruta T, Furuta M,
Morita K, Imoto I, Omura K and Inazawa J: The tumor suppressive
microRNA miR-218 targets the mTOR component Rictor and inhibits AKT
phosphorylation in oral cancer. Cancer Res. 71:5765–5778. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S,
Guo X, Wang B, Gang Y, Zhang Y, et al: MiR-218 inhibits invasion
and metastasis of gastric cancer by targeting the Robo1 receptor.
PLoS Genet. 6:e10008792010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Small EM and Olson EN: Pervasive roles of
microRNAs in cardiovascular biology. Nature. 469:336–342. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guan B, Wu K, Zeng J, Xu S, Mu L, Gao Y,
Wang K, Ma Z, Tian J, Shi Q, et al: Tumor-suppressive microRNA-218
inhibits tumor angiogenesis via targeting the mTOR component RICTOR
in prostate cancer. Oncotarget. 8:8162–8172. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao Y, Wu K, Chen Y, Zhou J, Du C, Shi Q,
Xu S, Jia J, Tang X, Li F, et al: Beyond proliferation: KLF5
promotes angiogenesis of bladder cancer through directly regulating
VEGFA transcription. Oncotarget. 6:43791–43805. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Incoronato M, Urso L, Portela A, Laukkanen
MO, Soini Y, Quintavalle C, Keller S, Esteller M and Condorelli G:
Epigenetic regulation of miR-212 expression in lung cancer. PLoS
One. 6:e277222011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Leite KR, Tomiyama A, Reis ST,
Sousa-Canavez JM, Sañudo A, Camara-Lopes LH and Srougi M: MicroRNA
expression profiles in the progression of prostate cancer-from
high-grade prostate intraepithelial neoplasia to metastasis. Urol
Oncol. 31:796–801. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Grammatikakis I, Gorospe M and Abdelmohsen
K: Modulation of cancer traits by tumor suppressor microRNAs. Int J
Mol Sci. 14:1822–1842. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Venkataraman S, Birks DK, Balakrishnan I,
Alimova I, Harris PS, Patel PR, Handler MH, Dubuc A, Taylor MD,
Foreman NK and Vibhakar R: MicroRNA 218 acts as a tumor suppressor
by targeting multiple cancer phenotype-associated genes in
medulloblastoma. J Biol Chem. 288:1918–1928. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Folkman J: What is the evidence that
tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Karumanchi SA, Merchan J and Sukhatme VP:
Renal cancer: Molecular mechanisms and newer therapeutic options.
Curr Opin Nephrol Hypertens. 11:37–42. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Folkman J: Angiogenesis in cancer,
vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Aishima S, Taguchi K, Sugimachi K, Asayama
Y, Nishi H, Shimada M, Sugimachi K and Tsuneyoshi M: The role of
thymidine phosphorylase and thrombospondin-1 in angiogenesis and
progression of intrahepatic cholangiocarcinoma. Int J Surg Pathol.
10:47–56. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ferrara N: VEGF and the quest for tumour
angiogenesis factors. Nat Rev Cancer. 2:795–803. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jacobsen J, Grankvist K, Rasmuson T, Bergh
A, Landberg G and Ljungberg B: Expression of vascular endothelial
growth factor protein in human renal cell carcinoma. BJU Int.
93:297–302. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wöhrle FU, Daly RJ and Brummer T:
Function, regulation and pathological roles of the Gab/DOS docking
proteins. Cell Commun Signal. 7:222009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sattler M, Mohi MG, Pride YB, Quinnan LR,
Malouf NA, Podar K, Gesbert F, Iwasaki H, Li S, Van Etten RA, et
al: Critical role for Gab2 in transformation by BCR/ABL. Cancer
Cell. 1:479–492. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Y, Sheng Q, Spillman MA, Behbakht K
and Gu H: Gab2 regulates the migratory behaviors and E-cadherin
expression via activation of the PI3K pathway in ovarian cancer
cells. Oncogene. 31:2512–2520. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bentires-Alj M, Gil SG, Chan R, Wang ZC,
Wang Y, Imanaka N, Harris LN, Richardson A, Neel BG and Gu H: A
role for the scaffolding adapter GAB2 in breast cancer. Nat Med.
12:114–121. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gu H, Pratt JC, Burakoff SJ and Neel BG:
Cloning of p97/Gab2, the major SHP2-binding protein in
hematopoietic cells, reveals a novel pathway for cytokine-induced
gene activation. Mol Cell. 2:729–740. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang Y, Wu J, Demir A, Castillo-Martin M,
Melamed RD, Zhang G, Fukunaga-Kanabis M, Perez-Lorenzo R, Zheng B,
Silvers DN, et al: GAB2 induces tumor angiogenesis in NRAS-driven
melanoma. Oncogene. 32:3627–3637. 2013. View Article : Google Scholar : PubMed/NCBI
|
